With the US Phase IIb study results now expected around mid-2020, we have examined the study design and our expectations for the results. Separately, we have looked beyond the current study and indication to the application of Destiny Pharma’s products in infections associated with biofilms. Our valuation is £70.2m, or 160p per share.
10 Dec 2019
Destiny Pharma - Eyes on the Phase IIb prize
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Destiny Pharma - Eyes on the Phase IIb prize
Destiny Pharma Plc (DEST:LON) | 14.8 -1 (-31.4%) | Mkt Cap: 14.1m
- Published:
10 Dec 2019 -
Author:
Dr Nathaniel Calloway -
Pages:
16
With the US Phase IIb study results now expected around mid-2020, we have examined the study design and our expectations for the results. Separately, we have looked beyond the current study and indication to the application of Destiny Pharma’s products in infections associated with biofilms. Our valuation is £70.2m, or 160p per share.